Compare Krispy Kreme Inc (DNUT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs TransMedics Group Inc — how do they compare? Krispy Kreme Inc trades at $3.02 (market cap $521.37M), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 5.3× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and TransMedics Group Inc for 24 Days on average.
| DNUT | TMDX | |
|---|---|---|
Market Cap | $521.37M | $2.74B |
Volume | 2,293,015 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $150.42 |
52-Week Low | $2.87 | $61.99 |
Typical Hold Time | 45 Days | 24 Days |
Enterprise Value | $1.76B | $3.13B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $515.77M in 2025, with a negative net income margin of -33.88%, though revenue remains stable at $1.52B. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, alongside seasonal product launches like the Pokémon doughnut collection.
The outlook is mixed; analyst consensus leans buy (50%) with a low P/S of 0.34 offering value, but profitability challenges and legal overhangs pose significant risks. Cash flow improved in 2025, yet high debt and negative ROE of -14.43% demand caution for stock investors seeking turnaround potential amid competitive pressures.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
